In a move to bolster its cell therapies offering, Astellas has agreed to partner with Adaptimmune Therapeutics to co-develop and co-commercialise up to three stem-cell derived allogeneic T-cell therapies. The deal combines Adaptimmune's capabilities to generate a range of cell therapies, including target-specific T-cell and chimeric antigen receptors, with Astellas’ expertise, technology platforms and resources. Just one day prior to the Astellas deal, Adaptimmune announced that its SPEAR T-cell platform delivered partial responses across four different solid tumour indications, sending the company’s share price soaring 200%.